Public Release: 

Stopping liver cancer in its tracks

University of Tokyo


IMAGE: (Left) AIM is taken up into healthy liver cells, where it inhibits lipid storage and prevents steatosis, an illness caused by the buildup of excess lipid inside cells. (Right) In... view more

Credit: © 2014 Toru Miyazaki.

This news release is available in Japanese.

A University of Tokyo research group has discovered that AIM (Apoptosis Inhibitor of Macrophage), a protein that plays a preventive role in obesity progression, can also prevent tumor development in mice liver cells. This discovery may lead to a therapy for hepatocellular carcinoma (HCC), the most common type of liver cancer and the third most common cause of cancer deaths.

Professor Toru Miyazaki's group at the Laboratory of Molecular Biomedicine from Pathogenesis, in the Faculty of Medicine has shown that AIM (also known as CD5L) accumulates on the cell membrane of HCC cells, where it triggers the complement cascade, a highly efficient process of eliminating cancerized cells. Experiments showed that mice unable to produce AIM fed on a high-fat diet for a year developed multiple liver tumors. Additionally, when the same type of mice on the same diet for 45 weeks, at which point they would have already developed HCC, showed no signs of HCC after treatment with AIM, indicating that cancerous cells were being destroyed.

The group had previously found AIM, and identified its supportive role for the immune system and a protective role in obesity progression of fat cells. Now they have found that AIM is involved in eliminating cancerized cells. The group revealed that AIM accumulates on the surface of mice HCC cells, but not on normal cells and showed that AIM interferes with proteins that normally suppress the complement cascade, triggering a process that leads to necrosis and elimination of the cancerous cells.

HCC can be caused by several factors including a high-fat diet, and this form of liver cancer is increasing due to rising obesity. "Because of its resistance to chemotherapy, HCC is now the third most common cause of cancer-related deaths, and therefore, it is certainly desirable to identify the preventive machinery against HCC. The most exciting finding for us is that AIM behaves in two different ways in preventing liver diseases. It enters into normal hepatocytes to keep them skinny, which prevents the buildup of fat inside cells seen in steatosis, whereas it accumulates on the surface of HCC cells to kill them," says Professor Miyazaki. Given that AIM also gathers on the surface of human HCC, it may be possible to develop AIM as a therapy for human HCC. Professor Miyazaki continues, "It is surprising that we do have an excellent system to eliminate undesired cancer cells, and that this system may certainly be therapeutically applicable not only to HCC, but also more broadly to other types of cancer."


Journal article

Natsumi Maehara, Satoko Arai, Mayumi Mori, Yoshihiro Iwamura, Jun Kurokawa, Toshihiro Kai, Shunsuke Kusunoki, Kaori Taniguchi, Kazutaka Ikeda, Osamu Ohara, Ken-ichi Yamamura, and Toru Miyazaki, "Circulating AIM Prevents Hepatocellular Carcinoma through Complement Activation," Cell Reports 9, 1-14 (forthcoming: 9 October 2014).


Laboratory of Molecular Biomedicine from Pathogenesis, Center for Disease Biology and Integrative Medicine
Faculty of Medicine
The University of Tokyo

Contact information

Professor Toru Miyazaki
Laboratory of Molecular Biomedicine from Pathogenesis, Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo
Secretary: Inoue Shiho, Inoue Yukari
Tel: +81-3-5841-1436
Fax: +81-3-5841-1438

Graduate School of Medicine press officer & contact information

Ryosuke Nobukawa
General Affairs Office
Graduate School of Medicine, The University of Tokyo
Tel: +81-3-5841-3304
Fax: +81-3-5841-8585

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.